BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN)

Core Insights - BioMarin Pharmaceutical Inc. (BMRN) is experiencing profitable growth but has seen its share prices decline to the lowest levels in a decade, indicating a disconnect between performance and market expectations [1]. Group 1: Company Performance - By the end of October, BioMarin reported growing numbers, suggesting a positive trend in its financial performance despite the falling expectations from the market [1]. Group 2: Market Sentiment - The shares of BioMarin have fallen significantly, reflecting a broader market sentiment that may not align with the company's actual growth metrics [1].